Ovarian reserve in patients with multiple sclerosis: A systematic review and meta‐analysis

Abstract

AbstractObjectiveTo summarize recent evidence about ovarian reserve markers in women affected by multiple sclerosis (MS) compared with healthy controls, as women with MS seem to be characterized by lower anti‐Müllerian hormone (AMH) levels.MethodsThe research was conducted using PubMed (MEDLINE), Scopus, ClinicalTrial.gov, OVID and Cochrane Library from inception of each database to June 30, 2022. Studies comparing ovarian reserve markers between women with MS and healthy controls were considered eligible for inclusion. The primary outcome was serum AMH (ng/mL) levels. Results were reported as pooled odds ratio (OR) for categorical outcomes and as mean difference (MD) for continuous variables, with their 95% confidence intervals (CIs). The random effect model of DerSimonian and Laird was adopted for all analyses. A P‐value less than 0.05 was considered significant.ResultsSerum AMH circulating levels were not significantly different (MD −0.25, 95% CI −0.83 to 0.32; P = 0.390), as well as blood levels of follicle‐stimulating hormone or ovarian volume. However, antral follicle count (AFC) and estradiol blood levels were significantly lower, and luteinizing hormone (LH) levels were significantly higher in women with MS than in controls.ConclusionA significant difference in AFC, estradiol and LH levels was observed, but not for AMH levels.